In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors
暂无分享,去创建一个
H Bönig | U. Banning | J. Verheyen | M. Hannen | H. Bönig | D. Körholz | A. Wundes | D Körholz | W Nürnberger | U Banning | J Verheyen | M Hannen | H-J Laws | A Wundes | Y-M Kim | W. Nürnberger | H. Laws | Y.M. Kim
[1] S. Burdach,et al. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation , 1997, Bone Marrow Transplantation.
[2] S. Burdach,et al. Time course of interferon-gamma production deficiency after autologous and allogeneic stem cell transplantation for malignancies. , 1995, Experimental hematology.
[3] S. Burdach,et al. The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses. , 1997, Blood.
[4] D. Rubinstein,et al. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution. , 1994, Cancer research.
[5] H. Tilg,et al. Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy. , 1995, Cytokine.
[6] A. Lindemann,et al. Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2. , 1997, European journal of cancer.
[7] U. Banning,et al. Additive effects of infection and neutropenia on the induction of granulocytopoietic activity in vivo , 1999, Cancer.
[8] P. Lissoni,et al. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients. , 1998, British Journal of Cancer.
[9] J. Kovach,et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. , 1991, Blood.
[10] T. Olencki,et al. Interleukin‐2: Use in solid tumors , 1993, Stem cells.
[11] P. Tagliaferri,et al. Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects. , 1998, American journal of clinical oncology.
[12] S. Burdach,et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Fisher,et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] J. Falkenburg,et al. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients , 1991 .
[15] H. Heslop,et al. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation , 1991, British journal of haematology.
[16] C. Peschle,et al. Adoptive immunotherapy with high-dose interleukin-2: kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level. , 1991, Blood.
[17] Banning,et al. Regulation of Interleukin‐2 Induced Interleukin‐5 and Interleukin‐13 Production in Human Peripheral Blood Mononuclear Cells , 2000, Scandinavian journal of immunology.
[18] J. Falkenburg,et al. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. , 1991, Blood.
[19] Anthony,et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. , 1989, Blood.
[20] H. Heslop,et al. IL‐2 infusion abrogates humoral immune responses in humans , 1992, Clinical and experimental immunology.
[21] A. Beaulieu,et al. Effects of interleukin-2 on gene expression in human neutrophils. , 1995, Blood.
[22] S. Burdach,et al. Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors. , 1994, Experimental hematology.
[23] L Davies,et al. Bone marrow transplant. , 1985, Nursing times.
[24] Hanns-Martin Lorenz,et al. Differential Role for IL‐2 and IL‐15 in the Inhibition of Apoptosis in Short Term Activated Human Lymphocytes , 1997, Scandinavian journal of immunology.